Profile Response Detail

Molecular Profile GNAQ Q209L PTEN R173S
Therapy Refametinib
Indication/Tumor Type ocular melanoma
Response Type predicted - sensitive
Create By spatt
Update By djd


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
GNAQ Q209L PTEN R173S ocular melanoma predicted - sensitive Refametinib Phase I Actionable In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733). 23434733
PubMed Id Reference Title Details
(23434733) Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Full reference...